Neoleukin Therapeutics Inc
Change company Symbol lookup
Select an option...
NLTX Neoleukin Therapeutics Inc
CTO CTO Realty Growth Inc
WHR Whirlpool Corp
OTIS Otis Worldwide Corp
GME GameStop Corp
ECF Ellsworth Growth and Income Fund Ltd
SILK Silk Road Medical Inc
HLVX Hillevax Inc
AIZ Assurant Inc
NOTV Inotiv Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value
Company profile

Neoleukin Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. The Company's lead product candidate, NL-201, is an interleukin-2 (IL-2)/ interleukin-15 (IL-15) immunotherapy designed to eliminate binding to the alpha subunit of the IL-2 receptor (also known as CD25) while enhancing binding to the beta and gamma subunits. NL-201 is designed to mimic the therapeutic activity of the cytokines IL-2 and IL-15 for the treatment of various types of cancer, including renal cell carcinoma (RCC), melanoma and hematological malignancies. Its Neoleukin platform uses a set of advanced computational algorithms and methods to design functional de novo proteins. NL-201 holds promise in combination with cell therapy to expand and maintain populations of transplanted CAR-T and natural killer (NK) cells.

Closing Price
$0.59
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
40,499

10-day average volume:
60,091
40,499

CLASS ACTION UPDATE for OLO, RAD and UIS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

7:11 am ET November 23, 2022 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / November 23, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

OLO Shareholders Click Here: https://www.zlk.com/pslra-1/olo-inc-loss-submission-form?prid=33987&wire=1

RAD Shareholders Click Here: https://www.zlk.com/pslra-1/rite-aid-lawsuit-loss-submission-form?prid=33987&wire=1

UIS Shareholders Click Here: https://www.zlk.com/pslra-1/unisys-corporation-lawsuit-submission-form?prid=33987&wire=1

* ADDITIONAL INFORMATION BELOW *

Levi & Korsinsky, LLP, Wednesday, November 23, 2022, Press release picture

Olo Inc. (NYSE:OLO)

This lawsuit is on behalf of all persons and entities that purchased shares of Olo's Class A common stock between August 11, 2021 and August 11, 2022.

Lead Plaintiff Deadline : November 28, 2022

TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/olo-inc-loss-submission-form?prid=33987&wire=1

According to the filed complaint, (1) Subway was ending its contract with Olo; (2) Olo's key business metric - active locations - could not continue to grow as defendants touted due to the loss of Subway's business; and (3) as a result of the above, defendants' statements about Olo's business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

Rite Aid Corporation (NYSE:RAD)

RAD Lawsuit on behalf of: investors who purchased April 14, 2022 - September 28, 2022

Lead Plaintiff Deadline : December 19, 2022

TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/rite-aid-lawsuit-loss-submission-form?prid=33987&wire=1

According to the filed complaint, during the class period, Rite Aid Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) despite representations to the contrary, the number of new members that the Elixir pharmacy benefit management services business was adding during the selling season ending on January 1, 2023 was in material decline; (ii) Rite Aid was likely to recognize a significant charge for the impairment of goodwill related to Elixir due to a decrease in "lives" covered by Elixir's pharmacy benefit management services business; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Unisys Corporation (NYSE:UIS)

UIS Lawsuit on behalf of: investors who purchased August 3, 2022 - November 7, 2022

Lead Plaintiff Deadline : January 10, 2023

TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/unisys-corporation-lawsuit-submission-form?prid=33987&wire=1

According to the filed complaint, during the class period, Unisys Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's 2022 financial guidance was significantly overstated; (ii) accordingly, once the truth was revealed, it was likely that the Company would be required to negatively revise its 2022 financial guidance; (iii) in addition to the foregoing, material weaknesses existed in the Company's internal control over financial reporting; and (iv) as a result of all of the foregoing, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Eduard Korsinsky, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com

SOURCE: Levi & Korsinsky, LLP





View source version on accesswire.com:

https://www.accesswire.com/728053/CLASS-ACTION-UPDATE-for-OLO-RAD-and-UIS-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders



comtex tracking

COMTEX_419539908/2457/2022-11-23T07:11:13

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.